U.S. Real Estate Stock News

Citizens coverage and mortgage rate shift move Tri Pointe Homes Tri Pointe Homes (TPH) gained 5.4% in morning trading after Citizens initiated coverage with a "Market Outperform" rating, coinciding with two year fixed mortgage rates slipping below 4% for the first time since August 2022. See our latest analysis for Tri Pointe Homes. The strong 1 day share price return of 8.68% and 7 day return of 12.20% build on a 90 day share price return of 14.18%, while the 3 year total shareholder return...

In early January 2026, an industry report indicated that Powder River Basin coal supply has tightened as several coal-fired power units are being retired later than previously planned, leaving producers like Peabody Energy with much of their expected 2026 output already under contract. This development highlights how Peabody’s focus on securing long-term coal supply agreements may support revenue visibility even as decarbonization pressures continue. We’ll now examine how tighter Powder...

Federal Home Loan Mortgage (FMCC) is back on many investors’ screens after a sharp 12.7% decline over the past 3 months and a 7.5% drop over the past month, prompting fresh questions on valuation. See our latest analysis for Federal Home Loan Mortgage. The recent pullback fits into a mixed picture for Federal Home Loan Mortgage, with the share price at US$10.08 after a 7.5% 30 day share price return decline and a very large 3 year total shareholder return. This suggests strong longer term...

In early January 2026, UGI Corporation drew attention as Hamlin Capital Management opened a new US$22.0 million position and Wall Street analysts issued an “Outperform” rating, while the company also managed operational events including a mall gas-odor investigation and ongoing gas main replacement work in Pennsylvania. Together, heightened institutional interest, positive analyst commentary, and visible utility field activity underscore how UGI’s regulated energy footprint and capital...

Alkermes (ALKS) shares are in focus after the U.S. FDA granted Breakthrough Therapy designation to alixorexton for narcolepsy type 1, based on phase 1 and Vibrance-1 phase 2 clinical data. See our latest analysis for Alkermes. At a share price of $29.66, Alkermes has seen a 7 day share price return of 4.95% and a 1 year total shareholder return of 5.63%, suggesting recent momentum after a softer 90 day share price return decline of 4.97% as attention turns to the alixorexton program. If this...

If you are wondering whether N-able's share price around US$7.31 actually reflects its underlying worth, you are not alone. This article is built to help you size that up clearly. Over the past week the stock is roughly flat at a 0.1% return, but that sits against a 4.2% decline over 30 days and a 19.7% decline over the past year, which can change how investors view both its potential and its risks. Recent coverage has focused on how N-able is positioned within the broader software and IT...

If you are looking at Ciena and wondering whether the current share price offers good value or is running ahead of itself, you are not alone. The stock closed at US$230.56, with a 6.3% decline over the last 7 days, a 3.9% gain over the last 30 days, and returns of 180.3% over 1 year, 351.3% over 3 years, and 332.5% over 5 years. This naturally raises questions about growth potential and changing risk perceptions. Recent coverage around Ciena has focused on its position in networking and...

If you are looking at Willis Lease Finance and asking whether the current share price still offers value, you are not alone. The answer depends heavily on how you choose to value the business. The stock last closed at US$155.82, with returns of 16.2% over the past week, 15.7% over the last month, 16.2% year to date, a 24.1% decline over the last year, and a very large gain over the past 5 years. Recent share price moves sit against a backdrop of ongoing interest in aircraft engine leasing...

If you have been wondering whether P10 is priced attractively right now, you are not alone. Many investors are asking the same question about what they are really paying for with this stock. P10 shares last closed at US$10.33, with recent returns of 4.4% over the past week, 1.2% over the past month, 4.4% year to date, and a 17.6% decline over the past year and 7.6% decline over three years. Recent market attention on P10 has been shaped by ongoing discussion around its role in the...

Immuneering Corporation recently reported updated Phase 2a data showing encouraging overall survival, response, and safety outcomes for its atebimetinib plus modified gemcitabine/nab-paclitaxel regimen in previously untreated pancreatic cancer patients, and confirmed plans to begin a pivotal Phase 3 trial in mid-2026. A key nuance is that the reported survival benefit is based on comparisons to historical MPACT trial benchmarks rather than a head-to-head control arm, which may influence how...

On 7 January 2026, the World Orphan Drug Alliance and Syndax Pharmaceuticals announced a collaboration to expand global access to Syndax’s first-in-class menin inhibitor Revuforj (revumenib) via a Managed Access Program for eligible patients outside the U.S. where local regulations and funding allow. This partnership broadens real-world use of Revuforj in difficult-to-treat KMT2A-rearranged and NPM1-mutated leukemias, potentially strengthening its clinical footprint beyond the U.S. approval...

In recent days, Tractor Supply has come under fresh scrutiny as Gordon Haskett downgraded the retailer ahead of its January 29, 2026 earnings release, citing softer same‑store sales expectations and limited visibility on long‑term growth targets. This comes as Tractor Supply balances slower revenue expansion, thinner gross margins than peers, and rising viral popularity on social media that is broadening its appeal beyond traditional rural customers. Next, we’ll explore how this downgrade,...

Morningstar, Inc. recently announced that Anne Bramman, a veteran finance leader with more than 30 years of experience across global companies, has been elected to its board of directors and appointed to the Audit and Compensation Committees. Her background as a former CFO and transformation leader in multiple industries positions her to influence Morningstar’s approach to financial oversight, modernization, and capital allocation. We will explore how Bramman’s extensive CFO and audit...

If you are wondering whether American Express is fairly priced after a strong run, this article will walk through what the current share price might be implying about future expectations. The stock last closed at US$375.61, with returns of 0.8% over the past week, 0.0% over the past month, 0.8% year to date, 29.4% over the past year and 226.7% over the past five years, which naturally raises questions about how much optimism is already in the price. Recent attention on American Express has...

Eagle Materials (EXP) has drawn fresh attention as investors weigh its recent share performance against fundamentals, including US$2,301.796m in revenue and US$446.799m in net income, alongside its current US$235.66 share price. See our latest analysis for Eagle Materials. The recent 1-day share price return of 6.66% and 7-day share price return of 11.45% point to building momentum, while the 0.75% 1-year total shareholder return and 115.09% 5-year total shareholder return show a much...

If you are wondering whether FTAI Aviation's share price still reflects good value after its recent run, you are not alone. The stock most recently closed at US$245.73, with returns of 16.8% over the past week, 34.9% over the past month, 16.8% year to date, 42.6% over the past year and a very large gain over the past 3 years and 5 years. Recent coverage has focused on FTAI Aviation's position within the aviation sector and investor interest in its business model. This has helped keep the...

Why Black Hills’ Ready Wyoming project matters for shareholders Black Hills (BKH) has just completed and energized its 260 mile, $350 million Ready Wyoming electric transmission expansion, linking its South Dakota and Wyoming systems and putting fresh attention on the stock. See our latest analysis for Black Hills. Despite the Ready Wyoming announcement and an upcoming 2025 earnings release in early February, Black Hills’ share price at $70.72 sits on a modest year to date gain of 1.54%,...

If you are wondering whether Masco's current share price offers real value or just noise, you are not alone. The stock recently closed at US$69.32, with returns of 7.5% over the last 7 days, 9.3% over 30 days, 7.5% year to date and a 2.1% decline over 1 year, alongside 40.9% and 34.9% returns over 3 and 5 years. Recent news flow around Masco has focused on its position in the broader capital goods space and how investors are weighing its long term prospects against shorter term sentiment...

If you are wondering whether Banco Latinoamericano de Comercio Exterior S. A is still attractively priced after its recent run, this article will walk through what the current share price might imply about value. The stock closed at US$43.45, with returns of 26.7% over the past year, even though the last 7 days and 30 days saw returns of a 0.8% decline and a 3.5% decline respectively. Recent interest around BLX has largely centered on its role as a specialist trade finance bank for Latin...

Compass (COMP) has drawn fresh attention after recent trading, with the stock showing sizable moves over the past month and past 3 months, even as the business continues to report a net loss alongside positive revenue growth. See our latest analysis for Compass. That momentum has not been limited to a few strong sessions, with a 90 day share price return of 82.39% and a 1 year total shareholder return of 140.00% pointing to building optimism around Compass’s prospects and risk profile at the...

Madison Square Garden Entertainment (MSGE) is back in focus after announcing that its 2025 Christmas Spectacular, starring the Radio City Rockettes, drew more than 1.2 million attendees, the production's highest level in 25 years. See our latest analysis for Madison Square Garden Entertainment. Against this backdrop, Madison Square Garden Entertainment’s recent news arrives after a stretch of strong share price momentum. The stock has a 90 day share price return of 31.70% and a 1 year total...

If you are wondering whether ACM Research at around US$53.22 is still a sensible entry point or if too much optimism is already baked in, you are not alone. The stock has seen sharp moves, with returns of 18.6% over the last week, 34.8% over the last month, 18.6% year to date, 240.7% over one year and 391.9% over three years. These shifts can influence how the market views its potential and its risk. Recent coverage has highlighted ACM Research as a key player supplying cleaning equipment to...

Recent analyst upgrades, led by UBS shifting Gap (GAP) to a more positive rating, have renewed investor focus on the retailer as the market evaluates its beauty offerings, handbag lines, Athleta brand and trends in store traffic. See our latest analysis for Gap. Those upgrades and reports around Gap's comeback sit against a share price of US$28.32, with a 90 day share price return of 43.76% and a 1 year total shareholder return of 20.92%. This suggests momentum has been building rather than...

For investors wondering whether FormFactor is still reasonably priced after its recent run, or if expectations are already reflected in the share price, this article walks through what the current price might be implying. The stock last closed at US$68.64, with returns of 16.0% over the past week, 18.1% over the past month, 16.0% year to date, 55.2% over 1 year and 172.9% over 3 years, while the 5 year return stands at 40.6%. These moves have put FormFactor on more investors' radars, and...